Amarin stock heads toward highest prices in more than a decade after new Vascepa FDA approval
December 13, 2019 at 18:27 PM EST
Amarin Corp.’s stock rises in the extended session Friday after being halted for half the trading day as the pharmaceutical company hikes its sales outlook following a Food and Drug Administration marketing approval that gives its drug Vascepa a wider use.